The biotech stock's price-to-earnings-to-growth (PEG) ratio is a super-low 0.58, according to the London Stock Exchange Group (LSEG). Any PEG ratio below 1.0 is viewed as an attractive valuation.
Companies on the 2024 Inc. 5000 are ranked according to percentage revenue growth over the last three years. They generated 874,940 jobs, $317 billion in revenue, and show where the economy is ...